Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Crucially for the 20262031 forecast period, Teva's generic manufacturing infrastructure which includes peptide synthesis capabilities positions it as a potential major player in the semaglutide and tirzepatide generic market that will open following patent expiries (semaglutide: US patent 2032
The dual GLP-1 and GIP receptor agonist mechanism that tirzepatide offers has shown remarkable results in clinical trials, and the compounded versions promise similar outcomes at a fraction of brand-name pricing
Neurological Research, 46 (2), 165-177
Cardiovascular therapeutics
US$ 29.82
US$ 26.43
US$ 24.10
US$ 24.75
